Personal care treatments

Emerging biologics, topical anti-inflammatories and systemic treatments for AD

Atopic dermatitis (AD), the most common inflammatory skin disease affecting children and adults, leads to significant alterations in the quality of life (QoL) of patients, especially when the disease is insufficiently controlled. In recent years, however, approvals of targeted treatments such as crisaborole (Eucrisa; Pfizer) and dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) have led to dramatic improvements in symptom control and outcomes for patients with of MA.

Despite the availability of targeted therapies for the disease, some AD patients who receive only topical agents consequently experience uncontrolled disease and decreased quality of life, highlighting the need for better treatment options for this patient population. .1

New therapies with diverse mechanisms of action have recently shown promise in filling current gaps in the treatment of AD.

A mini symposium at the 4th Annual Revolutionizing Atopic Dermatitis 2022 Conference, held virtually and in Baltimore, Maryland, highlighted emerging oral systemic therapies, anti-inflammatory agents and promising biologics for AD.2

Symposium moderator Jonathan Silverberg, MD, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, D.C., opened the session with a discussion on topical anti-inflammatory therapies emerging for AD. Additionally, Silverberg provided an extensive discussion and update on emerging biologics for the treatment of the disease.

David Rosmarin, MD, FAAD, clinical researcher and vice president for research and education at Tufts Medical Center, Boston, Massachusetts, also detailed emerging oral systemic therapies for AD during the mini-symposium session. Recently FDA-approved oral therapies for AD include selective Janus kinase (JAK) inhibitors abrocitinib (Cibinqo; Pfizer), baricitinib (Olumiant; Eli Lilly and Company), and upadacitinib (Rinvoq; AbbVie ). Recent approvals of these drugs have broadened the therapeutic landscape for AD, offering the possibility of improving outcomes in symptom control in patients with inadequate or intolerable responses to standard therapies.

“For many years we have had topical corticosteroids and calcineurin inhibitors as mainstays of topical anti-inflammatory treatments in AD,” Rosmarin commented. “It’s an exciting time to have additional options to help patients.”

Although effective, JAK inhibitors contain black box warnings, given clinical trial observations of cardiovascular disease safety signals with this class of drugs.3 “Every drug has side effects,” Rosmarin explained, “and we must always ensure that the benefits outweigh the risks when treating patients with AD and improving the patient’s quality of life. “

“We are seeing new options for AD in several areas, and each new treatment has its pros and cons,” Rosmarin added. “Some medications may be better for itching, some are quicker, and some have a different oral route or injection frequency. With additional options, we can provide optimal care for our patients.

References:

  1. Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Inadequate disease control, treatment dissatisfaction, and impaired quality of life in US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(5):1571-1585.
  2. Rosmarin D, Silverberg J. Mini-Symposium 4: Emerging Systemic Therapies in AD. Presented at: 4th Annual Revolutionizing Atopic Dermatitis Conference, April 9-11, 2022, Baltimore, Maryland.
  3. US Food and Drug Administration. The FDA requires warnings about the increased risk of serious heart events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Published September 1, 2021. Accessed April 8, 2022. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart -related-events-cancer-blood-clots-and-death